Recent Updates on CAR T-Cell Therapy: FDA Approvals and Patent Litigation
Bio Law Blog
FEBRUARY 21, 2021
On Feb. 5, 2021, the Food and Drug Administration (FDA) granted approval for a new CAR T-cell therapy, Breyanzi® (lisocabtagene maraleucel), to Juno Therapeutics, a subsidiary of Bristol-Myers Squibb (BMS). Breyanzi® is indicated for the treatment of relapsed/refractory large B-cell lymphoma in adults who have not responded to at least two other systemic treatments.
52 
Let's personalize your content